ClinicalTrials.gg
RecruitingNCT06583811Updated Sep 4, 2024

Remifentanil and Remimazolam to Limit Patient Movement

An interventional study of Remifentanil in Long-Eye Surgeries, sponsored by Egymedicalpedia. Recruiting at 1 site in Egypt. Open to participants aged 40 Years to 50 Years. Per ClinicalTrials.gov, last updated 2024-09-04.

Sponsored by Egymedicalpedia · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Primary completion was expected by Jan 2025, 1 year 10 months ago, but the record still lists the study as recruiting.
  • Started Jul 2024; still recruiting 2 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
40 Years to 50 Years
Sex
All
01

Study summary

Local anesthetics (LA) may be administered by injection (retrobulbar, peribulbar, subconjunctival, lid, or facial block) or by instillation (topical anesthesia), Considerable drawbacks of local anesthesia in these patients include the fact that a few patients can remain comfortable on an operating table for procedures that exceed two or three hours.

Sedation may be helpful with LA to decrease the experience of discomfort, movement and anxiety, which may in turn positively influence hemodynamic parameters, patient satisfaction, and overall improve surgical safety. Sedatives used in eye surgeries include benzodiazepines, opioids, alpha-adrenoceptor agonists, and propofol.

Read the detailed description

Ophthalmic surgery is a precise surgical procedure that requires absolute immobilization. Many ophthalmic procedures can be performed safely in an outpatient setting, using local anesthesia.

Propofol is currently the most commonly used intravenous anesthetic. It has a rapid onset of action, a short half-life and is associated with rapid recovery of cognitive ability. However, propofol can lead to injection pain, propofol infusion syndrome, and hemodynamic and respiratory depression. Therefore, there is a need for new anesthetic drugs with high efficacy and fewer side effects while providing stable and controllable anesthesia.

Remifentanil is a short-acting esterase metabolized opioid with analgesic and sedative effects. Its half-life is about 5-10 min so that it can be titrated closely in response to changes in intraoperative requirements and with a low risk of accumulation.

Remimazolam is a novel ultrashort-acting benzodiazepine agonist that works on γ-aminobutyric acid type A (GABA-A) receptors to reduce neuronal excitation and thereby achieve hypoactivity and sedation in the body. Remimazolam is metabolized by a nonspecific esterase, and the metabolite has no pharmacological effect, which allows prolonged infusion without accumulation.

It provides rapid anesthesia and arousal while stabilizing hemodynamics and produces less depression of respiration, making it more suitable for use in elderly and hemodynamically unstable patients.

02

Conditions studied

  • Long-Eye Surgeries
03

In context

Lead sponsor

Egymedicalpedia is the lead sponsor of 58 studies on the registry; 13 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age > 40 years.
  • Both sexes.
  • American Society of Anesthesiology (ASA) physical status I-III.
  • Undergoing long-eye surgeries under local anesthesia using peribulbar block with an expected surgical time of more than one hour.

Exclusion criteria

Exclusion Criteria:

  • Patients on aspirin or anticoagulants.
  • Allergy to any study medication.
  • Drug abuse.
  • Uncontrolled hypertension.
  • Hyperthyroidism.
  • Frequent cough.
  • Impaired hearing.
  • Severe liver and kidney dysfunction.
  • Neurological or psychological disorders.
  • Partial or failed block.
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
70 participants (estimated)

Study arms

  • Active comparator
    Group A: Remifentanil Group

    About 35 Patients will receive Remifentanil bolus of 1 μg/kg over 30 seconds followed by a continuous infusion of 0.03-0.05 μg/kg/min.

    Drug: Remifentanil

  • Active comparator
    Group B: Remimazolam Group

    About 35 Patients will receive remimazolam bolus of 0.2mg/kg followed by a continuous infusion of 0.3-0.5 μg/kg/h.

    Drug: Remifentanil

Interventions

  • to compare remifentanil and remimazolam to limit patient movement during long-eye surgeries under local anesthesia.

    Also known as: emimazolam

06

What researchers measure

Primary outcomes

  1. Eye Movement

    Incidence of patients who are not moving their Eyes during long eye surgery

    Time frame: from 0 hours to 4 hours after the procedure

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2024 (actual). Primary completion is estimated for Jan 2025, 5 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 30, 2024
First posted
Sep 4, 2024
StartActual
Jul 10, 2024
Primary completionEst.
Jan 1, 2025
CompletionEst.
Jan 10, 2025
Last update
Sep 4, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 4, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06583811
Lead sponsor
Egymedicalpedia
Collaborators
Al-Azhar University
Responsible party
Sponsor
First posted
Sep 4, 2024
Start date
Jul 10, 2024
Primary completion
Jan 1, 2025 (estimated)
Completion
Jan 10, 2025 (estimated)
Last update
Sep 4, 2024

Study contacts

Ahmed M. Elnagar, M.D
Contact
Ahmed.elnaggar@azhar.edu.eg
+201007529357

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Remifentanil

Start the discussion